# A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

> **NCT04571398** · — · UNKNOWN · sponsor: **Apricity Health, Inc** · enrollment: 100 (estimated)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** ApricityRx mobile application

## Key facts

- **NCT ID:** NCT04571398
- **Lead sponsor:** Apricity Health, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-19
- **Primary completion:** 2022-10-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571398, "A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04571398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*